search results for

refine results

sort by

Date
Relevance

result type

Articles
Video

Wires
Press Releases

EpiPen competitor Auvi-Q comes back Feb. 14 with a pricing scheme that will blow your mind

Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.

Source: CNBC.com

Kaleo Auvi-Q list price 6x more than EpiPen

CNBC's Meg Tirrell reports Kaleo is bringing back EpiPen competitor Auvi-Q, but that it will be listed at $4,500.

Source: CNBC.com

Mallinckrodt to pay $100M to settle FTC charges

Mallinckrodt is to pay $100 million to settle FTC charges that it illegally maintained a monopoly of a special drug used on infants. CNBC's Meg Tirrell reports.

Source: CNBC.com

Mallinckrodt erases losses, says they settled with FTC

CNBC's Meg Tirrell reports that Mallinckrodt has settled with the FTC over a potential monopoly situation over one of its drugs.

Source: CNBC.com

Bayer, Monsanto tout jobs, investment pledge to Trump, but analysts question how much is new

After a meeting with President-elect Donald Trump, Bayer and Monsanto pledged jobs and investment, but is this spending new? Analysts have their doubts.

Source: CNBC.com

Bayer pledges billions in US investments

According to Trump's transition team, Bayer will commit to $8 billion in new research and development jobs in the U.S. CNBC's Meg Tirrell reports.

Source: CNBC.com

Collaboration in a world where everything is connected

Technology has the potential to answer our biggest questions, solve some of our toughest challenges and help us better understand the world around us.

Source: CNBC.com

Closing Bell Exchange: Whole new world in technology

Discussing the current state of the markets with with Meg Green, Meg Green & Associates; Keith Bliss, Cuttone & Co.; and Holly Liss, BTIG.

Source: CNBC.com

Gilead CEO: M&A is top of mind for us this year

John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.

Source: CNBC.com

Mylan CEO: Trump a very business-minded, solution-oriented individual

Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.

Source: CNBC.com